Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket

References

• Aborehab, N. M., Elnagar, M. R., & Waly, N. E. (2021). Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF‐7 human breast cancer cell line. Journal of Biochemical and Molecular Toxicology, 35(2), e22638. https://doi.org/10.1002/jbt.22638
   PubMed Web of Science ®Google Scholar
• Al-Rashood, S. T., Hamed, A. R., Hassan, G. S., Alkahtani, H. M., Almehizia, A. A., Alharbi, A., Al-Sanea, M. M., & Eldehna, W. M. (2020). Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 831–839. https://doi.org/10.1080/14756366.2020.1743281
   PubMed Web of Science ®Google Scholar
• Antonsson, B., Conti, F., Ciavatta, A., Montessuit, S., Lewis, S., Martinou, I., Bernasconi, L., Bernard, A., Mermod, J. J., Mazzei, G., Maundrell, K., Gambale, F., Sadoul, R., & Martinou, J. C. (1997). Inhibition of Bax channel-forming activity by Bcl-2. Science (New York, N.Y.), 277(5324), 370–372. https://doi.org/10.1126/science.277.5324.370
   PubMed Web of Science ®Google Scholar
• Balah, A., Ezzat, O., & Akool, E.-S. (2018). Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-β/Smad signaling pathway in rat liver. International Immunopharmacology, 65, 493–502. https://doi.org/10.1016/j.intimp.2018.09.033
   PubMed Web of Science ®Google Scholar
• Ballard, P., Bradbury, R. H., Harris, C. S., Hennequin, L. F. A., Hickinson, M., Johnson, P. D., Kettle, J. G., Klinowska, T., Leach, A. G., Morgentin, R., Pass, M., Ogilvie, D. J., Olivier, A., Warin, N., & Williams, E. J. (2006). Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorganic & Medicinal Chemistry Letters, 16(6), 1633–1637. https://doi.org/10.1016/j.bmcl.2005.12.028
   PubMed Web of Science ®Google Scholar
• Bonomi, P. (2003). Erlotinib: A new therapeutic approach for non-small cell lung cancer. Expert Opinion on Investigational Drugs, 12(8), 1395–1401. https://doi.org/10.1517/13543784.12.8.1395
   PubMed Web of Science ®Google Scholar
• Borenfreund, E., & Puerner, J. A. (1985). Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicology Letters, 24(2-3), 119–124. https://doi.org/10.1016/0378-4274(85)90046-3
   PubMed Web of Science ®Google Scholar
• Crawford, E. D., & Wells, J. A. (2011). Caspase substrates and cellular remodeling. Annual Review of Biochemistry, 80, 1055–1087. https://doi.org/10.1146/annurev-biochem-061809-121639
   PubMed Web of Science ®Google Scholar
• Dearden, J. C. (2003). In silico prediction of drug toxicity. Journal of Computer-Aided Molecular Design, 17(2–4), 119–127. https://doi.org/10.1023/a:1025361621494
   PubMed Web of Science ®Google Scholar
• Denizot, F., & Lang, R. (1986). Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods, 89(2), 271–277. https://doi.org/10.1016/0022-1759(86)90368-6
   PubMed Web of Science ®Google Scholar
• Eissa, I. H., Alesawy, M. S., Saleh, A. M., Elkaeed, E. B., Alsfouk, B. A., El-Attar, A.-A. M., & Metwaly, A. M. (2022). Ligand and structure-based in silico determination of the most promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase complex inhibitors among 3009 FDA approved drugs. Molecules, 27(7), 2287. https://doi.org/10.3390/molecules27072287
   PubMed Web of Science ®Google Scholar
• Eissa, I. H., Khalifa, M. M., Elkaeed, E. B., Hafez, E. E., Alsfouk, A. A., & Metwaly, A. M. (2021). In silico exploration of potential natural inhibitors against SARS-Cov-2 nsp10. Molecules, 26(20), 6151. https://doi.org/10.3390/molecules26206151
   PubMed Web of Science ®Google Scholar
• Eldehna, W. M., Hassan, G. S., Al-Rashood, S. T., Al-Warhi, T., Altyar, A. E., Alkahtani, H. M., Almehizia, A. A., & Abdel-Aziz, H. A. (2019). Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 322–332. https://doi.org/10.1080/14756366.2018.1547286
   PubMed Web of Science ®Google Scholar
• Elkady, H., Elwan, A., El-Mahdy, H. A., Doghish, A. S., Ismail, A., Taghour, M. S., Elkaeed, E. B., Eissa, I. H., Dahab, M. A., Mahdy, H. A., & Khalifa, M. M. (2022). New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 403–416. https://doi.org/10.1080/14756366.2021.2015343
   Web of Science ®Google Scholar
• Elkaeed, E. B., Eissa, I. H., Elkady, H., Abdelalim, A., Alqaisi, A. M., Alsfouk, A. A., Elwan, A., & Metwaly, A. M. (2022). A multistage in silico study of natural potential inhibitors targeting SARS-CoV-2 main protease. International Journal of Molecular Sciences, 23(15), 8407. https://doi.org/10.3390/ijms23158407
   PubMed Web of Science ®Google Scholar
• Elkaeed, E. B., Elkady, H., Belal, A., Alsfouk, B. A., Ibrahim, T. H., Abdelmoaty, M., Arafa, R. K., Metwaly, A. M., & Eissa, I. H. (2022). Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors among 3009 clinical and FDA-approved related drugs. Processes, 10(3), 530. https://doi.org/10.3390/pr10030530
   Web of Science ®Google Scholar
• Elkaeed, E. B., Khalifa, M. M., Alsfouk, B. A., Alsfouk, A. A., El-Attar, A.-A. M., Eissa, I. H., & Metwaly, A. (2022). The discovery of potential SARS-CoV-2 natural inhibitors among 4924 African metabolites targeting the papain-like protease: A multi-phase in silico approach. Metabolites, 12(11), 1122. https://doi.org/10.3390/metabo12111122
   PubMed Web of Science ®Google Scholar
• Elkaeed, E. B., Yousef, R. G., Elkady, H., Gobaara, I. M. M., Alsfouk, B. A., Husein, D. Z., Ibrahim, I. M., Metwaly, A. M., & Eissa, I. H. (2022). Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: In vitro anticancer and VEGFR-2 inhibitory effects. Molecules, 27(14), 4606. https://doi.org/10.3390/molecules27144606
   PubMed Web of Science ®Google Scholar
• Elkaeed, E. B., Youssef, F. S., Eissa, I. H., Elkady, H., Alsfouk, A. A., Ashour, M. L., El Hassab, M. A., Abou-Seri, S. M., & Metwaly, A. M. (2022). Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. International Journal of Molecular Sciences, 23(13), 6912. https://doi.org/10.3390/ijms23136912
   PubMed Web of Science ®Google Scholar
• Elmetwally, S. A., Saied, K. F., Eissa, I. H., & Elkaeed, E. (2019). Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorganic Chemistry, 88, 102944.
   Google Scholar
• Elnagar, M. R., Walls, A. B., Helal, G. K., Hamada, F. M., Thomsen, M. S., & Jensen, A. A. (2018). Functional characterization of α7 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. European Journal of Pharmacology, 826, 106–113. https://doi.org/10.1016/j.ejphar.2018.02.047
   PubMed Web of Science ®Google Scholar
• Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., Althaus, I. W., Gandhi, L., Shapiro, G. I., Nelson, J. M., Heymach, J. V., Meyerson, M., Wong, K.-K., & Jänne, P. A. (2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Research, 67(24), 11924–11932. https://doi.org/10.1158/0008-5472.CAN-07-1885
   PubMed Web of Science ®Google Scholar
• Ferreira, L. L., & Andricopulo, A. D. (2019). ADMET modeling approaches in drug discovery. Drug Discovery Today, 24(5), 1157–1165. https://doi.org/10.1016/j.drudis.2019.03.015
   PubMed Web of Science ®Google Scholar
• Furet, P., Caravatti, G., Lydon, N., Priestle, J. P., Sowadski, J. M., Trinks, U., & Traxler, P. (1995). Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411. Journal of Computer-Aided Molecular Design, 9(6), 465–472. https://doi.org/10.1007/BF00124317
   PubMed Web of Science ®Google Scholar
• Gandin, V., Ferrarese, A., Dalla Via, M., Marzano, C., Chilin, A., & Marzaro, G. (2015). Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Scientific Reports, 5, 16750. https://doi.org/10.1038/srep16750
   PubMed Web of Science ®Google Scholar
• Goh, G. B., Hodas, N. O., & Vishnu, A. (2017). Deep learning for computational chemistry. Journal of Computational Chemistry, 38(16), 1291–1307. https://doi.org/10.1002/jcc.24764
   PubMed Web of Science ®Google Scholar
• Huether, A., Höpfner, M., Baradari, V., Schuppan, D., & Scherübl, H. (2005). EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochemical Pharmacology, 70(11), 1568–1578. https://doi.org/10.1016/j.bcp.2005.09.007
   PubMed Web of Science ®Google Scholar
• Idakwo, G., Luttrell, J., Chen, M., Hong, H., Zhou, Z., Gong, P., & Zhang, C. (2018). A review on machine learning methods for in silico toxicity prediction. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews, 36(4), 169–191. https://doi.org/10.1080/10590501.2018.1537118
   PubMed Web of Science ®Google Scholar
• Ishikawa, T., Seto, M., Banno, H., Kawakita, Y., Oorui, M., Taniguchi, T., Ohta, Y., Tamura, T., Nakayama, A., Miki, H., Kamiguchi, H., Tanaka, T., Habuka, N., Sogabe, S., Yano, J., Aertgeerts, K., & Kamiyama, K. (2011). Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3, 2-d] pyrimidine scaffold. Journal of Medicinal Chemistry, 54(23), 8030–8050. https://doi.org/10.1021/jm2008634
   PubMed Web of Science ®Google Scholar
• Jia, Y., Quinn, C. M., Gagnon, A. I., & Talanian, R. (2006). Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Analytical Biochemistry, 356(2), 273–281. https://doi.org/10.1016/j.ab.2006.05.006
   PubMed Web of Science ®Google Scholar
• Kim, E. S. (2016). Olmutinib: First global approval. Drugs, 76(11), 1153–1157. https://doi.org/10.1007/s40265-016-0606-z
   PubMed Web of Science ®Google Scholar
• Kim, Y., Ko, J., Cui, Z., Abolhoda, A., Ahn, J. S., Ou, S.-H., Ahn, M.-J., & Park, K. (2012). The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Molecular Cancer Therapeutics, 11(3), 784–791. https://doi.org/10.1158/1535-7163.MCT-11-0750
   PubMed Web of Science ®Google Scholar
• Kruhlak, N., Benz, R., Zhou, H., & Colatsky, T. (2012). (Q) SAR modeling and safety assessment in regulatory review. Clinical Pharmacology and Therapeutics, 91(3), 529–534. https://doi.org/10.1038/clpt.2011.300
   PubMed Web of Science ®Google Scholar
• Kuida, K. (2000). Caspase-9. The International Journal of Biochemistry & Cell Biology, 32(2), 121–124. https://doi.org/10.1016/s1357-2725(99)00024-2
   PubMed Web of Science ®Google Scholar
• Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., Rabindran, S. K., McGinnis, J. P., Wissner, A., Sharma, S. V., Isselbacher, K. J., Settleman, J., & Haber, D. A. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resi…˙.stance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America, 102(21), 7665–7670. https://doi.org/10.1073/pnas.0502860102
   PubMed Web of Science ®Google Scholar
• Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., Rettig, W. J., Meyerson, M., Solca, F., Greulich, H., & Wong, K.-K. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27(34), 4702–4711. https://doi.org/10.1038/onc.2008.109
   PubMed Web of Science ®Google Scholar
• Li, P., Zhang, Q., Torossian, A., Li, Z-b., Xu, W-c., Lu, B., & Fu, S. (2012). Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. International Journal of Radiation Oncology, Biology, Physics, 83(3), e391–e397. https://doi.org/10.1016/j.ijrobp.2011.12.090
   PubMed Web of Science ®Google Scholar
• Liu, Y., & Gray, N. S. (2006). Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology, 2(7), 358–364. https://doi.org/10.1038/nchembio799
   PubMed Web of Science ®Google Scholar
• Lo, K. K.-W., Lee, T. K.-M., Lau, J. S.-Y., Poon, W.-L., & Cheng, S.-H. (2008). Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorganic Chemistry, 47(1), 200–208. https://doi.org/10.1021/ic701735q
   PubMed Web of Science ®Google Scholar
• Lyons, T. (2019). Targeted therapies for triple-negative breast cancer. Current Treatment Options in Oncology, 20(11), 1–13.
   Google Scholar
• Metwaly, A. M., Elkaeed, E. B., Alsfouk, B. A., Saleh, A. M., Mostafa, A. E., & Eissa, I. (2022). The computational preventive potential of the rare Flavonoid, Patuletin, isolated from Tagetes patula, against SARS-CoV-2. Plants, 11(14), 1886. https://doi.org/10.3390/plants11141886
   Google Scholar
• Metwaly, A. M., Elwan, A., El-Attar, A.-A. M., Al-Rashood, S. T., & Eissa, I. (2022). Structure-based virtual screening, docking, ADMET, molecular dynamics, and MM-PBSA calculations for the discovery of potential natural SARS-CoV-2 helicase inhibitors from the traditional Chinese medicine. Journal of Chemistry, 2022, 1-23.
   Google Scholar
• Mikhalev, A., Kon’shin, M., Kolla, V., Nazmetdinov, F. Y., & Vakhrin, M. (1997). Synthesis and antiinflammatory activity of 2-substituted cinchoninic and 1, 2, 4-triazolo [4, 3-a] quinoline-5-carboxylic acids. Pharmaceutical Chemistry Journal, 31(11), 600–602. https://doi.org/10.1007/BF02464278
   Google Scholar
• Nascimento, I., de Aquino, T. M., & da Silva-Júnior, E. (2022). Discovery, The new era of drug discovery: The power of computer-aided drug design (CADD). Letters in Drug Design & Discovery, 19(11), 951–955. https://doi.org/10.2174/1570180819666220405225817
   Web of Science ®Google Scholar
• Nasser, A. A., Eissa, I. H., Oun, M. R., El-Zahabi, M. A., Taghour, M. S., Belal, A., Saleh, A. M., Mehany, A. B. M., Luesch, H., Mostafa, A. E., Afifi, W. M., Rocca, J. R., & Mahdy, H. A. (2020). Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M. Organic & Biomolecular Chemistry, 18(38), 7608–7634. https://doi.org/10.1039/d0ob01557a
   PubMed Web of Science ®Google Scholar
• Norinder, U., & Bergström, C. A. (2006). Prediction of ADMET properties. ChemMedChem: Chemistry Enabling Drug Discovery, 1(9), 920–937. https://doi.org/10.1002/cmdc.200600155
   PubMed Web of Science ®Google Scholar
• Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366(1), 2–16. https://doi.org/10.1016/j.gene.2005.10.018
   PubMed Web of Science ®Google Scholar
• Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine, 2(3), e73. https://doi.org/10.1371/journal.pmed.0020073
   PubMed Web of Science ®Google Scholar
• Park, J. H., Liu, Y., Lemmon, M. A., & Radhakrishnan, R. (2012). Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. The Biochemical Journal, 448(3), 417–423. https://doi.org/10.1042/BJ20121513
   PubMed Web of Science ®Google Scholar
• Perlman, H., Zhang, X., Chen, M. W., Walsh, K., & Buttyan, R. (1999). An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death and Differentiation, 6(1), 48–54. https://doi.org/10.1038/sj.cdd.4400453
   PubMed Web of Science ®Google Scholar
• Pietenpol, J., & Stewart, Z. (2002). Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology, 181–182, 475–481. https://doi.org/10.1016/S0300-483X(02)00460-2
   PubMed Web of Science ®Google Scholar
• Sabt, A., Abdelhafez, O. M., El-Haggar, R. S., Madkour, H. M., Eldehna, W. M., El-Khrisy, E. E.-D. A., Abdel-Rahman, M. A., & Rashed, L. A. (2018). Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, in vitro biological evaluation, and QSAR studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 1095–1107. https://doi.org/10.1080/14756366.2018.1477137
   PubMed Web of Science ®Google Scholar
• Salvesen, G. S., & Riedl, S. J. (2008). Caspase mechanisms. In Programmed cell death in cancer progression and therapy (pp. 13–23). Springer.
   Google Scholar
• Sequist, L. V., Besse, B., Lynch, T. J., Miller, V. A., Wong, K. K., Gitlitz, B., Eaton, K., Zacharchuk, C., Freyman, A., Powell, C., Ananthakrishnan, R., Quinn, S., & Soria, J.-C. (2010). Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non–small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(18), 3076–3083. https://doi.org/10.1200/JCO.2009.27.9414
   PubMed Web of Science ®Google Scholar
• Sogabe, S., Kawakita, Y., Igaki, S., Iwata, H., Miki, H., Cary, D. R., Takagi, T., Takagi, S., Ohta, Y., & Ishikawa, T. (2013). Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Medicinal Chemistry Letters, 4(2), 201–205. https://doi.org/10.1021/ml300327z
   PubMed Web of Science ®Google Scholar
• Suleimen, Y. M., Jose, R. A., Suleimen, R. N., Arenz, C., Ishmuratova, M., Toppet, S., Dehaen, W., Alsfouk, A. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2022a). Isolation and in silico anti-SARS-CoV-2 papain-like protease potentialities of two rare 2-phenoxychromone derivatives from Artemisia spp. Molecules, 27(4), 1216. https://doi.org/10.3390/molecules27041216
   PubMed Web of Science ®Google Scholar
• Suleimen, Y. M., Jose, R. A., Suleimen, R. N., Arenz, C., Ishmuratova, M. Y., Toppet, S., Dehaen, W., Alsfouk, B. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2022b). Jusanin, a new flavonoid from Artemisia commutata with an in silico inhibitory potential against the SARS-CoV-2 main protease. Molecules, 27(5), 1636. https://doi.org/10.3390/molecules27051636
   PubMed Web of Science ®Google Scholar
• Suleimen, Y. M., Jose, R. A., Suleimen, R. N., Ishmuratova, M. Y., Toppet, S., Dehaen, W., Alsfouk, A. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2022c). Isolation and in silico SARS-CoV-2 main protease inhibition potential of Jusan Coumarin, a new dicoumarin from Artemisia glauca. Molecules, 27(7), 2281. https://doi.org/10.3390/molecules27072281
   PubMed Web of Science ®Google Scholar
• Taghour, M. S., Elkady, H., Eldehna, W. M., El-Deeb, N. M., Kenawy, A. M., Elkaeed, E. B., Alsfouk, A. A., Alesawy, M. S., Metwaly, A. M., & Eissa, I. H. (2022). Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 1903–1917. https://doi.org/10.1080/14756366.2022.2085693
   PubMed Web of Science ®Google Scholar
• Taghour, M. S., Mahdy, H. A., Gomaa, M. H., Aglan, A., Eldeib, M. G., Elwan, A., Dahab, M. A., Elkaeed, E. B., Alsfouk, A. A., Khalifa, M. M., Eissa, I. H., & Elkady, H. (2022). Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and antiproliferative evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 2063–2077. https://doi.org/10.1080/14756366.2022.2103552
   PubMed Web of Science ®Google Scholar
• Tormyshev, V. M., Trukhin, D. V., Rogozhnikova, O. Y., Mikhalina, T. V., Troitskaya, T. I., & Flinn, A. (2006). Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes. Synlett, 2006(16), 2559–2564. https://doi.org/10.1055/s-2006-951484
   Google Scholar
• Van Schaeybroeck, S., Kyula, J., Kelly, D. M., Karaiskou-McCaul, A., Stokesberry, S. A., Van Cutsem, E., Longley, D. B., & Johnston, P. G. (2006). Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells. Molecular Cancer Therapeutics, 5(5), 1154–1165. https://doi.org/10.1158/1535-7163.MCT-05-0446
   PubMed Web of Science ®Google Scholar
• Wang, J., & Lenardo, M. J. (2000). Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. Journal of Cell Science, 113(5), 753–757. https://doi.org/10.1242/jcs.113.5.753
   PubMed Web of Science ®Google Scholar
• Xuhong, J.-C., Qi, X.-W., Zhang, Y., & Jiang, J. (2019). Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. American Journal of Cancer Research, 9(10), 2103.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews. Cancer, 9(1), 28–39. https://doi.org/10.1038/nrc2559
   PubMed Web of Science ®Google Scholar
• Zhang, J.-H., Zhang, Y., & Herman, B. (2003). Caspases, apoptosis and aging. Ageing Research Reviews, 2(4), 357–366. https://doi.org/10.1016/s1568-1637(03)00026-6
   PubMed Web of Science ®Google Scholar
• Zhao, L., Ciallella, H. L., Aleksunes, L. M., & Zhu, H. (2020). Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling. Drug Discovery Today. 25(9), 1624–1638. https://doi.org/10.1016/j.drudis.2020.07.005
   PubMed Web of Science ®Google Scholar
• Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014). Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chemical Biology, 9(6), 1230–1241. https://doi.org/10.1021/cb500129t
   PubMed Web of Science ®Google Scholar